Renal Failure

Adults with latent autoimmune diabetes are 25% more likely to develop microvascular complications beginning in the decade after diagnosis when compared with adults with type 2 diabetes, suggesting that early identification through the measurement of diabetes-related autoantibodies can help reduce risk for adverse outcomes, according to findings from a post hoc analysis published in The Lancet Diabetes & Endocrinology.

A shorter length of stay of 3 days or less was safe for patients who underwent elective cardiac surgery, according to a poster presented at The Society of Thoracic Surgeons Annual Meeting and Exhibition.

Among patients with immunoglobulin A vasculitis, smoking is associated with renal involvement, while generalized purpura and pretreatment neutrophil-to-lymphocyte ratio predict both gastrointestinal and renal symptoms, according to findings published in Arthritis Research & Therapy.

AstraZeneca announced that the SGLT2 inhibitor dapagliflozin has been granted priority review from the FDA to reduce the risk for CV mortality or worsening HF in patients with HF with reduced ejection fraction with and without type 2 diabetes.

Among the top stories in endocrinology last week were the FDA’s decision to fast track the sodium-glucose cotransporter 2 inhibitor dapagliflozin to delay renal failure in patients with or without diabetes who also have with chronic kidney disease and a study that found adults with type 2 diabetes treated with dipeptidyl-peptidase IV inhibitors were more likely to develop pancreatic cancer than those who received other treatment.